Filing Details
- Accession Number:
- 0001209191-13-045762
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-09-26 16:16:09
- Reporting Period:
- 2013-09-24
- Filing Date:
- 2013-09-26
- Accepted Time:
- 2013-09-26 16:16:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1280600 | Acceleron Pharma Inc | XLRN | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 816284 | Celgene Corp /De/ | 86 Morris Avenue Summit NJ 07901 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-09-24 | 457,875 | $0.00 | 457,875 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2013-09-24 | 57,899 | $0.00 | 515,774 | No | 4 | J | Direct | |
| Common Stock | Acquisiton | 2013-09-24 | 1,990,446 | $0.00 | 2,506,220 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2013-09-24 | 666,667 | $15.00 | 3,172,887 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | J | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series C-1 Convertible Preferred Stock | Disposition | 2013-09-24 | 457,875 | $0.00 | 457,875 | $0.00 |
| Common Stock | Series E Convertible Preferred Stock | Disposition | 2013-09-24 | 36,496 | $0.00 | 57,899 | $0.00 |
| Common Stock | Series F Convertible Preferred Stock | Disposition | 2013-09-24 | 1,990,446 | $0.00 | 1,990,446 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | J | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- Upon closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Common Stock without payment of further consideration. The shares had no expiration date.
- Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock automatically converted at a ratio of 1-for-1.58645 into the number of shares of Common Stock shown in column 7 without payment of further consideration. The shares had no expiration date.
- Upon closing of the Issuer's initial public offering, each share of Series F Preferred Stock automatically converted into one share of Common Stock without payment of further consideration. The shares had no expiration date.
Billionaire Hedge Funds
